The history of BRUKINSA, maximising the potential of BTK inhibition
Chronic lymphocytic leukaemia
Marginal zone lymphoma
Waldenström's macroglobulinaemia
Full meeting recording
Panel Discussion
Patient case study: Complex cardiovascular history
Patient case study: multiple comorbidities and at risk of drug-drug interactions
The BSH CLL guidelines and evolving clinical practice
Patient case study: Young unmutated IGHV, mutated TP53 and bulky disease
Long-term outcomes with BRUKINSA
Full meeting recording
BRUKINSA: A next-generation BTK inhibitor - Dr Tal Munir
BSH Guidelines: BRUKINSA® in CLL - Dr Renata Walewska
When should BRUKINSA® be your BTK inhibitor of choice?
- Panel discussion and Q&A - Dr Mark Rafferty and panel
BRUKINSA: A next-generation BTK inhibitor - Dr Tal Munir
BSH Guidelines: BRUKINSA® in CLL - Dr Renata Walewska
When should BRUKINSA® be your BTK inhibitor of choice?
- Panel discussion and Q&A - Dr Dima El-Sharkawi and panel
If you have any queries or would like to request BRUKINSA materials, feel free to contact your local Key Account Manager. You can find their contact details on the Contact Us page.